Ikena (IKNA): Analyst Consensus Forecast

Symbol and logo of brand Ikena (IKNA)

The market price action of Ikena Oncology, Inc. (IKNA) reflects the dynamics of an asset currently valued at 275.92. Ikena Oncology, Inc. (IKNA) develops targeted therapies for specific neoplasms with rare mutations. The business attracts researchers through a flexible approach to therapy and generous stock options. To reduce costs and operational risks, the company outsources the initial phases of drug testing to specialized external contractors.

IKNA (ikenaoncology.com) Analyst Consensus Forecast history from 07/04/2022 to 08/09/2025

Analytical breakdowns for ikenaoncology.com (IKNA)

- price and consensus price forecast:
Fundamental company analysis:Ikena (IKNA)
Original product of Ikena Oncology, Inc.

Defensive assets are selected based on the stability of their operating model, which is evidenced by Ikena Oncology, Inc. (IKNA) effectively managing cross-border biomaterial flows and minimizing customs costs. This strategy is reflected in the consensus target price, which measures the market's median expectation of the issuer's fair value relative to industry targets to identify asset undervaluation.

Competing companies

ONC - Average Forecast Price|Analyst Consensus Forecast HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines Corp - Price Target Chart|AAPG - Price Target Chart|Average Forecast Price cgoncology.com|UroGen (URGN) - Price Target Chart|Broker Consensus Forecast BCAX|PSNL (Personalis Genomics) - Analyst Consensus Forecast|Consensus Target Erasca Corp (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast ymabs.com (YMAB)|Price Target Chart Aura Bio AURA|CADL: Broker Consensus Forecast|Accuray, Inc. - Analyst Consensus Forecast|Average Forecast Price SELLAS Life Sciences Group|ACTU: Analyst Consensus Forecast|Average Forecast Price citiusonc.com (CTOR)|Price Target Chart tuhurabio.com|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics Corp)|WHWK (Aadi Bioscience) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics)|CSBR - Consensus Target|XBIT: Consensus Target|Fair Value Consensus CVM (cel-sci.com)|OS Therapies Inc (OSTX) - Price Target Chart|Radiopharm Theranostics - Fair Value Consensus|ARTV (Artiva Biotherapeutics Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Adlai Nortye Ltd.|Consensus Target VERU (Veru)|Analyst Forecast Prices TPST|Price Target Chart Xilio XLO|Renovaro Inc. (RENB) - Average Forecast Price|MURA - Price Target Chart|Analyst Median Target Kairos Pharma KAPA|OKUR (OnKure Therapeutics) - Consensus Target|Average Forecast Price CytoMed (GDTC)|Price Target Chart Curis|Price Target Chart APLM|Price Target Chart tharimmune.com (THAR)|Consensus Target Advanced Biomed ADVB|Genprex, Inc - Consensus Target|Fair Value Consensus CLDI|sunshinebiopharma.com - Analyst Consensus Forecast|Fair Value Consensus XBIO (xeneticbio.com)|SLRX (Salarius Pharmaceuticals) - Consensus Target|PPBT - Analyst Median Target|Price Target Chart American Oncology Network Inc|BGNE (BeiGene) - Analyst Forecast Prices|Consensus Target CKPT (Checkpoint Therapeutics, Inc)|ELEV - Average Forecast Price|Analyst Consensus Forecast ICAD (iCAD Inc.)|Analyst Median Target Notable Labs (NTBL)|Viracta Therapeutics - Analyst Consensus Forecast|Average Forecast Price MorphoSys Inc|NAYA: Analyst Consensus Forecast|Ascentage (AAPGV) - Analyst Consensus Forecast